Camu camu and its applications in nutraceutics

The Amazonian forests are home to a shrub, the camu-camu, whose fruit could be of great help in the fight against obesity and metabolic diseases

This is described in our latest study published with the A-Mansia R&D team in the journal Metabolites.

Overweight, obesity, and their comorbidities are currently considered a major public health concern

Today considerable efforts are still needed to develop efficient strategies able to attenuate the burden of these diseases. Nutritional interventions, some with plant extracts, present promising health benefits.

In this study, we evaluated the action of Camu-Camu (Myrciaria dubia), an Amazonian fruit rich in polyphenols and vitamin C, on the prevention of obesity and associated disorders in mice and the abundance of Akkermansia muciniphila in both cecum and feces.

Methods :

We investigated the dose-response effects of Camu-Camu extract (CCE) in the context of high-fat-diet (HFD)-induced obesity. After 5 weeks of supplementation, we demonstrated that the two doses of CCE differently improved glucose and lipid homeostasis.

Results :

The lowest CCE dose (62.5 mg/kg) preferentially decreased non-HDL cholesterol and free fatty acids (FFA) and increased the abundance of A. muciniphila without affecting liver metabolism, while only the highest dose of CCE (200 mg/kg) prevented excessive body weight gain, fat mass gain, and hepatic steatosis. Both doses decreased fasting hyperglycemia induced by HFD. In conclusion, the use of plant extracts, and particularly CCE, may represent an additional option in the support of weight management strategies and glucose homeostasis alteration by mechanisms likely independent from the modulation of A. muciniphila abundance.

 Source : Abot A, Brochot A, Pomié N, Wemelle E, Druart C, Régnier M, Delzenne NM, de Vos WM, Knauf C, Cani PD. Camu-Camu Reduces Obesity and Improves Diabetic Profiles of Obese and Diabetic Mice: A Dose-Ranging Study. Metabolites. 2022 Mar 29;12(4):301. doi: 10.3390/metabo12040301. PMID: 35448490; PMCID: PMC9025096.

 

 

 

 

 

 

 

Research

Categorie

Archives

Enterosys welcomes its new assistant engineer

Manon Carratala Lasserre joined the Enterosys team in November 2022 and is in charge of service delivery. She obtained a Master’s degree in Immunology and infectious diseases at the Paul Sabatier University in Toulouse. During her internships, she first worked on...

Enterosys participates in Biofit 2022 in Strasbourg

With the highest attending rate of academics, TTOs and research institutions, BioFIT is the place where academia-industry collaborations get started. BioFIT has taken on a whole new dimension becoming the meeting point in Europe for tech transfer and for sourcing...

Enterosys will attend NutrEvent 2022 in Nantes

NutrEvent is the event dedicated to innovation in Food, Feed, Nutrition and Health. This year, NutrEvent is back for its 8th edition in a hybrid format. This hybrid event will be held both in-person and online. Enterosys will be present with a validated, complete and...

Enterosys welcomes its new business developer

This month, Pauline Caseilles joined the Enterosys team as a Scientific Business Developer. Her mission: to publicize Enterosys' service offerings. Pauline obtained a Master’s degree in Health Biology and a Specialized Mastere in Marketing and Sales also in the field...

Antioxidant and anti-inflammatory properties of maternal milk

The high hydrostatic pressure processing of donor milk may better protect preterm infants from gut and liver pathologies compared to Holder pasteurization, which is currently used in most human milk banks Preterm infants are highly susceptible to oxidative stress due...